Gore PFO closure trial
This article was originally published in The Gray Sheet
Executive Summary
W.L. Gore announces FDA go-ahead May 5 for a 700-patient clinical trial of its Helex septal occluder for patent foramen ovale closure to prevent recurrence of cryptogenic stroke or transient ischemic attack. The REDUCE trial will randomize patients to receive either the Helex with medical management or medical management alone. Gore is recruiting up to 50 trial sites in the U.S. and Nordic countries and will begin enrolling patients this summer. The firm says its primary endpoint of freedom from recurrent ischemic stroke, imaging confirmed transient ischemic attack, or death from stroke at two-year follow-up is unique. Other PFO closure devices in trials for stroke include NMT Medical's Starflex and AGA Medical's Amplatzer (1"The Gray Sheet" Dec. 9, 2007, p. 9)
You may also be interested in...
Study Establishes Link Between PFO And Cryptogenic Stroke In Older Patients
A new study shows a correlation between patent foramen ovale (PFO) and cryptogenic strokes in older patients
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.